Taisho Pharmaceutical Co., Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Taisho Pharmaceutical Co., Ltd.
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Hikma announced the launch of the pain relief solution in the US where it will be sold under the name Combogesic IV as part of a deal with Hyloris Pharmaceuticals.
Strides intends to keep US momentum going with Amneal-partnered generic Vascepa, where Hikma and Dr. Reddy’s have filed antitrust suits against Amarin over API supply. Meanwhile, the founder re-iterated ambitious goals set for Stelis and its CDMO business.
Sandoz nominated a new director candidate ahead of its annual meeting and Lantheus welcomed a familiar face as the new CEO. Meanwhile, Mallinckrodt strengthened its board with four new directors and Hikma announced another appointment this year.
- Topical Delivery
- Drug Delivery
- Other Names / Subsidiaries
- Hoepharma Holdings Sdn. Bhd.
- Taisho Toyama Pharmaceutical Co., Ltd.
- TOKUHON Corporation
- UPSA SAS
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.